Pharmaceutical partnerships
-
Lunai Bioworks, Inc. Launches: Formerly Renovaro, Now Focused on AI-Driven Biodefense and Drug Discovery
Renovaro Inc. (NASDAQ:RENB) rebranded as Lunai Bioworks, focusing on AI-powered biodefense, drug discovery, and advanced diagnostics. This follows its merger with BioSymetrics, bringing partnerships with Janssen, Pfizer, Merck, and others. Lunai’s platform uses multimodal AI for real-time biological signal analysis, enabling early detection, patient stratification, and therapeutic targeting. The stock will continue trading under the RENB ticker. CEO David Weinstein emphasizes the company’s commitment to addressing global health and security challenges with AI-driven solutions.
